

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/188586 A1

(51) International Patent Classification:
A61K 31/70 (2006.01) *A61K 31/7024* (2006.01)

(21) International Application Number:
PCT/US2021/022622

(22) International Filing Date:
16 March 2021 (16.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/990,337 16 March 2020 (16.03.2020) US

(71) Applicants: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, TX 78701 (US). **MOLECULIN BIOTECH, INC.** [US/US]; 5300 Memorial Drive, Suite 950, Houston, TX 77007 (US).

(72) Inventors: **PRIEBE, Waldemar**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **FOKT, Izabela**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **ZIELINSKI, Rafal**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **SKORRA, Stanislaw**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **PICKER, Donald**; c/o Moleculin Biotech, Inc., 5300 Memorial Drive, Suite 950, Houston, TX 77007 (US). **KLEMP, Walter**; c/o Moleculin Biotech, Inc., 5300 Memorial Drive, Suite 950, Houston, TX 77007 (US).

(74) Agent: **VOGES, Mark H.**; PARKER HIGHLANDER PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2021/188586 A1

(54) Title: METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF

(57) Abstract: The present invention relates to methods of treating and preventing viral diseases and infections comprising the administration of hexoses and analogs and their prodrugs thereof that inhibit glycolysis and/or glycosylation.